Aromatase inhibitor therapy and hair loss among breast cancer survivors
Authors:
- 7 November 2013
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 142 (2) , 435-443
Abstract
The objective of this study was to examine the associations between aromatase inhibitor therapy and hair loss or hair thinning among female breast cancer survivors. Data were analyzed from 851 female breast cancer survivors who responded to a hospital registry-based survey. Data on hair loss, hair thinning, demographic characteristics, and health habits were based on self-report; data on aromatase inhibitor therapy were collected on the survey and verified using medical record review. Logistic regression was used to estimate the odds ratios (ORs) and 95 % confidence intervals (CIs) for the associations between aromatase inhibitor therapy and the hair outcome variables adjusted for potential confounders, including age and chemotherapy treatment. The results showed that 22.4 % of the breast cancer survivors reported hair loss and 31.8 % reported hair thinning. In the confounder-adjusted analyses, breast cancer survivors who were within 2 years of starting aromatase inhibitor treatment at the time of survey completion were approximately two and a half times more likely to report reporting hair loss (OR 2.55; 95 % CI 1.19–5.45) or hair thinning (OR 2.33; 95 % CI 1.10–4.93) within the past 4 weeks compared to those who were never treated with an aromatase inhibitor. Current aromatase inhibitor use for two or more years at the time of the survey and prior use were significantly associated with hair thinning (current users, ≥2 years: OR 1.86; prior users: OR 1.62), but not hair loss. Findings from this study suggest that aromatase inhibitor use is associated with an increased risk of hair loss and hair thinning independent of chemotherapy and age; these side effects are likely due to the substantial decrease in estrogen concentrations resulting from treatment with this drug. Future research should focus on examining these associations in a prospective manner using more detailed and objective measures of hair loss and thinning.Keywords
This publication has 23 references indexed in Scilit:
- Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapyClimacteric, 2011
- Tolerance of adjuvant letrozole outside of clinical trialsThe Breast, 2008
- Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast CancerClinical Breast Cancer, 2008
- Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial SubstudyJournal of Clinical Oncology, 2007
- Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapyBreast Cancer Research and Treatment, 2007
- Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal womenCurrent Medical Research and Opinion, 2006
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17JNCI: Journal of the National Cancer Institute, 2005
- Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialThe Lancet, 2005
- ATAC trial updateThe Lancet, 2005